{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/coronavirus-covid-19/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f349cd0f-cb0c-5006-b63f-5a30fdaa06b8","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 40b18c08-acd9-4dcb-b1fe-ab8700c423a1 --><h2>Changes</h2><!-- end field 40b18c08-acd9-4dcb-b1fe-ab8700c423a1 -->","summary":null,"htmlStringContent":"<!-- begin item 2805fe00-bca5-4950-a125-ab8700c423a1 --><!-- begin field 8116dadd-313e-40de-9f63-ab8700c423a1 --><p><strong>February 2021</strong><strong> </strong>— minor update. A new guide to planning access to end-of-life care medicines during a pandemic has been included.</p><p><strong>January 2021</strong><strong> </strong>— minor update. Prevalence figures have been updated and information that a new more transmissible variant of COVID-19 emerged in December 2020 has been added to this topic, along with updated information on vaccine dose schedules.</p><p><strong>December 2020 </strong>— minor update. A new scenario on managing the long-term effects of COVID-19 has been added that includes definitions of acute, ongoing, post-COVID-19 and long COVID syndromes.  This is based on the <em>COVID-19 rapid guideline: managing the long-term effects of COVID-19</em>. </p><p><strong>December 2020 </strong>— minor update. Information that COVID-19 vaccine recipients should be monitored for 15 minutes after receiving the vaccine and that an MHRA protocol for the management of anaphylaxis and an anaphylaxis pack must also be available when the Pfizer/BioNtech vaccine is given has been added to this topic in line with the latest update to the NHS England (NHSE) <em>Standard operating procedure: COVID-19 local vaccination services deployment in community settings</em>, along with a link to primary care guidance on the COVID-19 vaccination programme.</p><p><strong>December 2020 </strong>— minor update. A new scenario on COVID-19 immunization has been added to this topic.</p><p><strong>August 2020 </strong>— minor update. Prevalence figures have been updated and information on complications of COVID-19 have been added.</p><p><strong>July 2020 </strong>— minor update. New rapid evidence summary and rapid guideline have been included.</p><p><strong>June 2020 </strong>— minor update. Information from the Public Health England report <em>Disparities in the risk and outcomes of COVID-19</em> about the prevalence of COVID-19 in BAME groups has been added to this topic. Information about global and UK cases has also been updated. New rapid guidelines have also been included.</p><p><strong>June 2020</strong> — minor update. Recommendations on how to manage people during the COVID-19 pandemic with vitamin B12 deficiency who normally receive intramuscular injections of vitamin B12 have been added in line with the British Society for Haematology (BSH) guidance on <em>Vitamin B12 replacement during the COVID-19 pandemic</em>.</p><p><strong>May 2020 </strong>— minor update. Prescribing information has been added in response to the National Institute for Health and Care Excellence (NICE)<em> COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 </em>to reflect the advice during the COVID-19 pandemic. </p><p><strong>May 2020 </strong>— minor update. A scenario has been added for Chronic kidney disease to incorporate recommendations from NICE rapid guidelines.</p><p><strong>May 2020 </strong>— minor update. Information on additional signs and symptoms, including skin rashes, have been added to the diagnosis section, prevalence information has been updated, and information that people with immunosuppression should undertaken shielding has been added.</p><p><strong>April 2020</strong> — minor update. Scenarios have been added for Concurrent medical conditions, Palliative care and Prescribing issues to incorporate recommendations from NICE rapid guidelines.  </p><p><strong>April 2020 </strong>— minor update. New rapid guidelines have been included.</p><p><strong>March 2020 </strong>— new topic. CKS topic written based on a literature search and on NICE rapid guidelines. </p><!-- end field 8116dadd-313e-40de-9f63-ab8700c423a1 --><!-- end item 2805fe00-bca5-4950-a125-ab8700c423a1 -->","topic":{"id":"6984fb85-3c40-5450-bda6-7957f9a560d7","topicId":"b76b302e-7ac5-44a1-aad7-ab8700c41ab2","topicName":"Coronavirus - COVID 19","slug":"coronavirus-covid-19","lastRevised":"Last revised in February 2021","chapters":[{"id":"d212a92c-0add-595b-a7d6-5a32867fe5f9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d145562-2683-52db-accf-a80bedd6bb5e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c52a3c97-1e7c-58b4-af86-0dd2f0b77865","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f349cd0f-cb0c-5006-b63f-5a30fdaa06b8","slug":"changes","fullItemName":"Changes"},{"id":"f026a20a-e43c-59e7-883d-f0d7a1dbdd1a","slug":"update","fullItemName":"Update"}]},{"id":"bfc8a3e9-5b8f-5b1f-9059-3f9b1843015d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1d7208d4-4be1-5109-a3fc-f5fc9070f775","slug":"goals","fullItemName":"Goals"},{"id":"b64f49e4-a62d-56cd-abcb-f82c407e52e7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"51ea8ac4-fd38-524d-8566-e42974bfa9c4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"216d80a9-a8e3-5739-b592-c2d9ddd176ea","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cde80e77-2bd9-5594-9200-fe3a6fef7fc3","slug":"qipp","fullItemName":"QIPP"},{"id":"a24c3e94-065a-5767-9d41-cb69868045fc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18477846-110b-5a6f-844c-2cfa1a84c39f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a15744df-f80f-5b08-8993-b289c88d56a1","slug":"definition","fullItemName":"Definition"},{"id":"814f7a41-46c7-5e8c-9763-f02d81a30777","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e0a5f4e3-6adc-56a8-a13a-460ca5f3c39a","slug":"complications","fullItemName":"Complications"},{"id":"cd8348b4-2bcc-59c6-9dbf-b420df79dbfd","slug":"public-health-response","fullItemName":"Public Health Response"},{"id":"11cbcb38-8a55-5f6a-8077-321789f26356","slug":"comparison-to-other-infections","fullItemName":"Comparison to Other Infections"},{"id":"448d1049-b54d-50a4-8a5e-aac889069c6f","slug":"disease-progression","fullItemName":"Disease Progression"}]},{"id":"020a4b1b-6b82-532a-8050-185d648bcf7d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc5a288c-4b1e-54d0-8244-d5ca25652c50","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"3c0ddcd5-473d-5a66-8ae2-7fa97ad2e887","slug":"suspected-coronavirus-infection","fullItemName":"Scenario: Suspected coronavirus infection"},{"id":"1e4e7529-8d5b-52a4-97cc-a86c6d93dfc8","slug":"immunization","fullItemName":"Scenario: Immunization"},{"id":"e148d0d4-0f10-53c6-94bf-27e92c5eb531","slug":"management-of-other-medical-conditions","fullItemName":"Scenario: Management of other medical conditions"},{"id":"18839f74-7d09-5801-9fc9-1ca496cccf09","slug":"palliative-care","fullItemName":"Scenario: Palliative care"},{"id":"ed0623a0-a868-5776-bbdb-09a5d64bd6d0","slug":"prescribing-issues","fullItemName":"Scenario: Prescribing issues"},{"id":"f6aa749f-0a06-5ca2-b3cd-e01327e4ef76","slug":"managing-long-term-effects","fullItemName":"Scenario: Managing long-term effects"},{"id":"8d7143f7-6842-52e2-8644-5060222c472f","slug":"clinical-resources","fullItemName":"Scenario: Clinical resources"}]},{"id":"ee648ec4-3617-53c8-b0d5-ade1caeb5cfb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ea7d7ae-64e1-581e-856d-9daa5d3570ba","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d29ccf56-f68d-5ce0-b726-09ba9ed827e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84321e07-ed6b-5815-b7a9-de40ab2acde2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfaeb9ab-79ce-5851-a900-fdd0ab56f8fd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73f8f10-2617-514f-b07d-8f52fb8e7f2f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"586fa044-aa51-5fdc-895a-922bedd17946","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"66b3f0cb-7cb5-5f38-8632-30b8411234e4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c52a3c97-1e7c-58b4-af86-0dd2f0b77865","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}